Cancers Associated with Human Gammaherpesviruses

Overview

Journal FEBS J

Specialty Biochemistry

Date 2021 Sep 18

PMID 34536980

Citations 27

Authors

Kwun Wah Wen

Linlin Wang

Joshua R Menke

Blossom Damania

Affiliations

Soon will be listed here.

Abstract

Epstein-Barr virus (EBV; human herpesvirus 4; HHV-4) and Kaposi sarcoma-associated herpesvirus (KSHV; human herpesvirus 8; HHV-8) are human gammaherpesviruses that have oncogenic properties. EBV is a lymphocryptovirus, whereas HHV-8/KSHV is a rhadinovirus. As lymphotropic viruses, EBV and KSHV are associated with several lymphoproliferative diseases or plasmacytic/plasmablastic neoplasms. Interestingly, these viruses can also infect epithelial cells causing carcinomas and, in the case of KSHV, endothelial cells, causing sarcoma. EBV is associated with Burkitt lymphoma, classic Hodgkin lymphoma, nasopharyngeal carcinoma, plasmablastic lymphoma, lymphomatoid granulomatosis, leiomyosarcoma, and subsets of diffuse large B-cell lymphoma, post-transplant lymphoproliferative disorder, and gastric carcinoma. KSHV is implicated in Kaposi sarcoma, primary effusion lymphoma, multicentric Castleman disease, and KSHV-positive diffuse large B-cell lymphoma. Pathogenesis by these two herpesviruses is intrinsically linked to viral proteins expressed during the lytic and latent lifecycles. This comprehensive review intends to provide an overview of the EBV and KSHV viral cycles, viral proteins that contribute to oncogenesis, and the current understanding of the pathogenesis and clinicopathology of their related neoplastic entities.

Citing Articles

The 'Oma's of the Gammas-Cancerogenesis by γ-Herpesviruses.

Banerjee A, Dass D, Mukherjee S, Kaul M, Harshithkumar R, Bagchi P Viruses. 2025; 16(12.

PMID: 39772235 PMC: 11680331. DOI: 10.3390/v16121928.

Structures of Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus virions reveal species-specific tegument and envelope features.

Zhen J, Chen J, Huang H, Liao S, Liu S, Yuan Y J Virol. 2024; 98(11):e0119424.

PMID: 39470208 PMC: 11575322. DOI: 10.1128/jvi.01194-24.

Understanding Metabolic Pathway Rewiring by Oncogenic Gamma Herpesvirus.

Choi U, Lee S J Microbiol Biotechnol. 2024; 34(11):2143-2152.

PMID: 39403716 PMC: 11637867. DOI: 10.4014/jmb.2407.07039.

Unlocking the Potential: Epstein-Barr Virus (EBV) in Gastric Cancer and Future Treatment Prospects, a Literature Review.

Corallo S, Lasagna A, Filippi B, Alaimo D, Tortorella A, Serra F Pathogens. 2024; 13(9).

PMID: 39338919 PMC: 11435077. DOI: 10.3390/pathogens13090728.

Human herpesvirus reactivation and its potential role in the pathogenesis of post-acute sequelae of SARS-CoV-2 infection.

Gaspar Z, Szabo B, Cegledi A, Lakatos B Geroscience. 2024; 47(1):167-187.

PMID: 39207648 PMC: 11872864. DOI: 10.1007/s11357-024-01323-9.

References

Ballestas M, Chatis P, Kaye K . Efficient persistence of extrachromosomal KSHV DNA mediated by latency-associated nuclear antigen. Science. 1999; 284(5414):641-4. DOI: 10.1126/science.284.5414.641. View

Liu X, Li Y, Peng S, Yu X, Li W, Shi F . Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1/3 ubiquitination. Cell Death Dis. 2018; 9(2):53. PMC: 5833833. DOI: 10.1038/s41419-017-0081-9. View

CALDWELL R, Brown R, Longnecker R . Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol. 2000; 74(3):1101-13. PMC: 111444. DOI: 10.1128/jvi.74.3.1101-1113.2000. View

Mendoza M, Er E, Blenis J . The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011; 36(6):320-8. PMC: 3112285. DOI: 10.1016/j.tibs.2011.03.006. View

Gera J, Mellinghoff I, Shi Y, Rettig M, Tran C, Hsu J . AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2003; 279(4):2737-46. DOI: 10.1074/jbc.M309999200. View

Everly Jr D, Mainou B, Raab-Traub N . Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol. 2004; 78(24):13470-8. PMC: 533955. DOI: 10.1128/JVI.78.24.13470-13478.2004. View

Kitagawa N, Goto M, Kurozumi K, Maruo S, Fukayama M, Naoe T . Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction. EMBO J. 2000; 19(24):6742-50. PMC: 305895. DOI: 10.1093/emboj/19.24.6742. View

Lu F, Wikramasinghe P, Norseen J, Tsai K, Wang P, Showe L . Genome-wide analysis of host-chromosome binding sites for Epstein-Barr Virus Nuclear Antigen 1 (EBNA1). Virol J. 2010; 7:262. PMC: 2964674. DOI: 10.1186/1743-422X-7-262. View

Tomlinson C, Damania B . The K1 protein of Kaposi's sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol. 2004; 78(4):1918-27. PMC: 369501. DOI: 10.1128/jvi.78.4.1918-1927.2004. View

10.

Brinkmann M, Glenn M, Rainbow L, Kieser A, Henke-Gendo C, Schulz T . Activation of mitogen-activated protein kinase and NF-kappaB pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J Virol. 2003; 77(17):9346-58. PMC: 187392. DOI: 10.1128/jvi.77.17.9346-9358.2003. View

11.

Sharp T, Wang H, Koumi A, Hollyman D, Endo Y, Ye H . K15 protein of Kaposi's sarcoma-associated herpesvirus is latently expressed and binds to HAX-1, a protein with antiapoptotic function. J Virol. 2001; 76(2):802-16. PMC: 136811. DOI: 10.1128/jvi.76.2.802-816.2002. View

12.

Anders P, Montgomery N, Montgomery S, Bhatt A, Dittmer D, Damania B . Human herpesvirus-encoded kinase induces B cell lymphomas in vivo. J Clin Invest. 2018; 128(6):2519-2534. PMC: 5983348. DOI: 10.1172/JCI97053. View

13.

Vega F, Chang C, Medeiros L, Udden M, Cho-Vega J, Lau C . Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol. 2004; 18(6):806-15. DOI: 10.1038/modpathol.3800355. View

14.

Inagaki T, Sato Y, Ito J, Takaki M, Okuno Y, Yaguchi M . Direct Evidence of Abortive Lytic Infection-Mediated Establishment of Epstein-Barr Virus Latency During B-Cell Infection. Front Microbiol. 2021; 11:575255. PMC: 7888302. DOI: 10.3389/fmicb.2020.575255. View

15.

Jha H, Yang K, El-Naccache D, Sun Z, Robertson E . EBNA3C regulates p53 through induction of Aurora kinase B. Oncotarget. 2015; 6(8):5788-803. PMC: 4467402. DOI: 10.18632/oncotarget.3310. View

16.

Hsieh A, Truitt M, Ruggero D . Oncogenic AKTivation of translation as a therapeutic target. Br J Cancer. 2011; 105(3):329-36. PMC: 3172900. DOI: 10.1038/bjc.2011.241. View

17.

Naranatt P, Akula S, Chandran B . Characterization of gamma2-human herpesvirus-8 glycoproteins gH and gL. Arch Virol. 2002; 147(7):1349-70. DOI: 10.1007/s00705-002-0813-7. View

18.

Le Roux A, Kerdiles B, Walls D, Dedieu J, Perricaudet M . The Epstein-Barr virus determined nuclear antigens EBNA-3A, -3B, and -3C repress EBNA-2-mediated transactivation of the viral terminal protein 1 gene promoter. Virology. 1994; 205(2):596-602. DOI: 10.1006/viro.1994.1687. View

19.

Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N . Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med. 1995; 333(11):693-8. DOI: 10.1056/NEJM199509143331103. View

20.

Casola S, Otipoby K, Alimzhanov M, Humme S, Uyttersprot N, Kutok J . B cell receptor signal strength determines B cell fate. Nat Immunol. 2004; 5(3):317-27. DOI: 10.1038/ni1036. View